Zai Lab (ZLAB) investor relations material

Executive summary

• Total revenue for Q1 2026 was $99.6 million, down 6% year-over-year, mainly due to lower ZEJULA sales, competitive pressures, and pricing adjustments, partially offset by growth in XACDURO and NUZYRA.

• The company advanced its global pipeline, with pivotal studies and strong clinical data for zoci in SCLC and epNECs, and new collaborations with Amgen and Boehringer Ingelheim.

• Preparations for KarXT launch in China are underway, with regulatory reviews for TIVDAK and TTFields, and positive Phase 3 results for povetacicept and elegrobart.

• Commercial business remains regionally profitable, supported by a strong balance sheet and new leadership to enhance execution.

• Cash, cash equivalents, restricted cash, and short-term investments totaled $761.3 million as of March 31, 2026.

Financial highlights

• Q1 2026 total revenue was $99.6 million, down 6% year-over-year, with net product revenue at $95.6 million, a 10% decrease, mainly due to lower ZEJULA and VYVGART sales.

• ZEJULA revenue declined 39% to $30.0 million; XACDURO revenue surged 667% to $8.6 million; NUZYRA also saw strong growth.

• R&D expenses increased 8% year-over-year to $65.6 million, driven by higher license fees and clinical trial costs.

• SG&A expenses rose 3% year-over-year to $65.1 million.

• Net loss increased to $51.0 million from $48.4 million in Q1 2025; loss per share was $0.05.

Outlook and guidance

• Sequential product revenue growth is expected over the next nine months, with near-term pressure through 2026 and a return to growth anticipated in 2027.

• KarXT launch in China expected in Q2 2026, with preparations for NRDL listing in 2027 and multiple regulatory milestones for TIVDAK, TTFields, and pipeline assets.

• Continued focus on operational efficiency, disciplined capital allocation, and supporting near-term launches and long-term growth.

• Sufficient liquidity is expected to fund operations for at least the next 12 months.